Brown Capital Management LLC Lowers Position in Inogen, Inc. (NASDAQ:INGN)

Brown Capital Management LLC reduced its stake in shares of Inogen, Inc. (NASDAQ:INGN) by 20.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,558,458 shares of the medical technology company’s stock after selling 392,478 shares during the period. Brown Capital Management LLC owned approximately 6.57% of Inogen worth $15,117,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Divisadero Street Capital Management LP boosted its position in Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after buying an additional 2,046,766 shares during the period. Vanguard Group Inc. grew its holdings in shares of Inogen by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock worth $11,492,000 after purchasing an additional 65,954 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Inogen by 29.3% in the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after buying an additional 129,307 shares during the period. Meros Investment Management LP boosted its position in Inogen by 1.6% during the 2nd quarter. Meros Investment Management LP now owns 397,209 shares of the medical technology company’s stock valued at $3,229,000 after buying an additional 6,385 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after acquiring an additional 132,287 shares during the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on INGN. StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Friday, November 8th.

Inogen Stock Down 0.3 %

INGN stock opened at $9.46 on Thursday. The business has a 50 day moving average of $9.74 and a 200 day moving average of $9.59. Inogen, Inc. has a twelve month low of $4.93 and a twelve month high of $13.33. The firm has a market cap of $225.34 million, a PE ratio of -4.20 and a beta of 1.04.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.